A method of increasing vaginal lubrication comprising the use of hydriodic acid syrup. The hydriodic acid syrup is orally administered in the preferred embodiment.

Patent
   RE36320
Priority
Apr 02 1992
Filed
Nov 26 1997
Issued
Sep 28 1999
Expiry
Apr 02 2012
Assg.orig
Entity
Small
0
1
all paid
1. A method of increasing vaginal lubrication in an adult human female in need of said treatment, said treatment consisting essentially of increasing the amount of transudate present in the vagina, comprising orally administering to the female an effective amount of hydriodic acid syrup.
2. A method of claim 1 wherein the hydriodic acid syrup further comprises 140 ml of hydriodic acid, 550 ml of purified water and 450 g of dextrose.
3. A method of claim 1 wherein the effective amount of hydriodic acid syrup is approximately 0.5-3.0 teaspoons of hydriodic acid syrup.
4. A method of claim 3 wherein the effective amount of hydriodic acid syrup is added to approximately 8 ounces of water before administration. 5. A method of increasing vaginal lubrication in an adult human female in need of said treatment, said treatment consisting essentially of increasing the amount of transudate present in the vagina, comprising orally administering to the female an effective amount of an aqueous solution of hydriodic acid.

This application is a continuation-in-part of U.S. patent application Ser. No. 07/862,454, filed Apr. 2, 1992, now U.S. Pat No. 5,231,423, issued Jan. 25, 1994 the teachings of which are incorporated herein by reference.

The normal sexual response begins with sexual arousal which causes genital vasocongestion that results in vaginal lubrication. The lubrication is due to the formation of a transudate in the vagina which, in conjunction with genital congestion, produces the so-called orgasmic platform prior to orgasm. Sexual stimuli and healthy vaginal tissue are prerequisites for genital vasocongestion and vaginal lubrication, (HARRISON'S PRINCIPLES OF INTERNAL MEDICINE, 12th ed., ed Wilson, J. D., et al. p. 301, McGraw-Hill Inc., New York (1991)).

Illnesses that impair neurological function, such as diabetes mellitus, may prevent normal sexual arousal. Pelvic diseases, such as vaginitis or endometriosis may also interfere with the normal sexual response. More commonly, decreased sexual response is due to psychological factors such as feelings of guilt, stresses such as anxiety, depression, fatigue or interpersonal conflicts which lead to failure of the vasocongestive response and prevent sufficient vaginal lubrication. (HARRISON'S PRINCIPLES OF INTERNAL MEDICINE, 12th ed., ed. Wilson, J. D., et al. p. 301, McGraw-Hill Inc., New York (1991)). In addition, vaginal lubrication in response to sexual stimuli may decrease as a woman ages. Insufficient, or absence of, vaginal lubrication may result in unsatisfying, or painful sexual relations.

Women experiencing stress may seek professional counseling by a therapist, physician or psychiatrist to overcome such problems and achieve normal sexual response. However, this option is often costly and time-consuming. Women suffering from a physical illness may be able to obtain relief through treatment of the underlying physical illness.

Alternatively, a number of creams or ointment preparations are commercially available for artificial lubrication. However, these preparation are often messy and inconvenient to use. Moreover, physical application of these artificial preparations are not always hygienic, and may introduce contaminants to the vaginal area, leading to irritation or infection. Thus, the need exists for a neat, hygienic, and convenient method of stimulating vaginal lubrication.

This invention relates to a method of increasing, or stimulating vaginal lubrication in an adult human female by using hydriodic acid in an aqueous solution. In the method of the present invention, the hydriodic acid is administered orally, as hydriodic syrup. Approximately 24 hours after oral administration, the amount of transudate present in the vagina is increased, resulting in increased lubrication of the vagina.

Oral administration of hydriodic acid to increase vaginal lubrication eliminates the problems associated with the application of creams and ointments to the vaginal area, thus simplifying preparation for sexual encounters and enhancing sexual satisfaction. Moreover, the risk of infection associated with external application of artificial lubricants is greatly reduced if not all together eliminated with the present invention.

This invention is based upon the discovery that an aqueous solution of hydriodic acid can heighten sexual desire, including increasing the amount of transudate present in the vagina, resulting in increased vaginal lubrication.

Hydriodic acid is a clear colorless, or pale yellow liquid, an aqueous solution of hydrogen iodide, which is a gas at ordinary temperature. Hydriodic acid is also known as anhydrous hydriodic acid, hydrogen iodide (HI), hydrogen monoiodide or hydriodic. (The Merck Index, Merck & Co.. Inc., 10th Ed. (1983)). Typically, hydriodic acid has been used as an expectorant, especially in the treatment of whooping cough (Pertussis).

As disclosed in the parent patent application, it has now been discovered that an aqueous solution of hydriodic acid has aphrodisiac properties, as confirmed through its use by an adult human female. The hydriodic acid of that, and the present, invention consists of hydriodic acid syrup comprised of hydriodic acid, water and dextrose. Hydriodic acid syrup was orally administered (ingested) to the subject. After approximately 24 hours, an aphrodisiac effect was experienced by the subject. The terms "aphrodisiac" or "heightened sexual desire", for the purposes of the present invention, refer to the following physical manifestations including clitoral swelling, nipple erection, contraction of the vaginal musculature, and a general tingling sensation.

Specifically, after oral administration of hydriodic acid syrup, the female subject experienced increased vaginal lubrication. The term "increased vaginal lubrication", as used herein, refers to an increased amount of transudate present in the vagina above the amount of transudate present in the vagina above the amount of transudate present in the unstimulated state.

Thus, the method of increasing vaginal lubrication in a human female described herein, comprises administering to a female in need of said treatment an effective amount of hydriodic acid syrup, comprising hydriodic acid, water and dextrose. As described in the Exemplification below, an effective amount of hydriodic syrup for an adult human female weighing approximately 165 pounds, is about 0.5 to 3.0 teaspoons of hydriodic acid syrup in 8 ounces of tap water. It is understood that higher or lower amounts of hydriodic acid syrup would be used for heavier or lighter subjects as in the purview of one skilled in the art. Thus, as a result of Applicant's discovery, a method is now provided for a neat, hygienic and convenient means of increasing vaginal lubrication in a human female.

The invention will be further illustrated by the following non-limiting Exemplification:

Exemplification

Hydriodic acid solution was purchased from Eli Lilly and Company, of Indianapolis, Ind., referred to as hydriodic acid syrup. Hydriodic acid syrup can also be prepared by combining hydriodic acid with purified water and dextrose. For example, 140 ml of hydriodic acid is mixed with 550 ml of purified water. To this mixture, 450 g of dextrose is added and dissolved by agitation. Quantity sufficient of purified water is then added to bring the volume to 1000 ml, and the solution is filtered.

The syrup was administered orally to a female human, 52 years of age, weighing approximately 165 pounds. About 0.5 to 3.0 teaspoons of the hydriodic acid syrup was admixed with approximately 8 ounces of tap water and then ingested. An aphrodisiac effect, as defined above, including increased vaginal lubrication, was experienced within approximately 24 hours.

Equivalents

Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Reilly, Susann R.

Patent Priority Assignee Title
Patent Priority Assignee Title
4670256, Sep 23 1985 V VALHALLA CORPORATION, C O CHARLES A MCCLURE, P O BOX 1168, TAMPA, FL 33601 A DE CORP Vaginal conditioning for sexual activity
//
Executed onAssignorAssigneeConveyanceFrameReelDoc
Nov 26 1997Rainburst, LLC(assignment on the face of the patent)
Jan 13 1999REILLY, SUSANNRainburst, LLCASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0099580705 pdf
Date Maintenance Fee Events
Nov 03 1999M283: Payment of Maintenance Fee, 4th Yr, Small Entity.
Nov 03 1999M286: Surcharge for late Payment, Small Entity.
May 08 2003M2552: Payment of Maintenance Fee, 8th Yr, Small Entity.
Jun 07 2007REM: Maintenance Fee Reminder Mailed.
Aug 23 2007M2553: Payment of Maintenance Fee, 12th Yr, Small Entity.
Aug 23 2007M2556: 11.5 yr surcharge- late pmt w/in 6 mo, Small Entity.


Date Maintenance Schedule
Sep 28 20024 years fee payment window open
Mar 28 20036 months grace period start (w surcharge)
Sep 28 2003patent expiry (for year 4)
Sep 28 20052 years to revive unintentionally abandoned end. (for year 4)
Sep 28 20068 years fee payment window open
Mar 28 20076 months grace period start (w surcharge)
Sep 28 2007patent expiry (for year 8)
Sep 28 20092 years to revive unintentionally abandoned end. (for year 8)
Sep 28 201012 years fee payment window open
Mar 28 20116 months grace period start (w surcharge)
Sep 28 2011patent expiry (for year 12)
Sep 28 20132 years to revive unintentionally abandoned end. (for year 12)